Literature DB >> 20606328

Effect of all-trans-retinoic acid on the development of chronic hypoxia-induced pulmonary hypertension.

Erquan Zhang1, Baohua Jiang, Ayumu Yokochi, Junko Maruyama, Yoshihide Mitani, Ning Ma, Kazuo Maruyama.   

Abstract

BACKGROUND: An earlier study showed that all-trans-retinoic acid (ATRA) prevents the development of monocrotalin-induced pulmonary hypertension (PH). The purpose of the present study was to determine the effect of ATRA on another model of chronic hypoxia-induced PH. METHODS AND
RESULTS: Male Sprague-Dawley rats were given 30 mg/kg ATRA or vehicle only by gavage once daily for 14 days during hypobaric hypoxic exposure. Chronic hypoxic exposure induced PH, right ventricular hypertrophy (RVH), and hypertensive pulmonary vascular changes. Quantitative morphometry of the pulmonary arteries showed that ATRA treatment significantly reduced the percentage of muscularized arteries in peripheral pulmonary arteries only with an external diameter between 15 and 50 microm. ATRA treatment also significantly reduced the medial wall thickness in small muscular arteries only with an external diameter between 50 and 100 microm. Unfortunately, these reductions did not accompany the lowering of pulmonary artery pressure nor decrease in RVH. Chronic hypoxia-induced PH rats with ATRA had a loss in body weight. Chronic hypoxia increased the expression of endothelial nitric oxide synthase in the lung on western blotting and immunohistochemistry, in which ATRA treatment had no effect.
CONCLUSIONS: The administration of ATRA might not have a therapeutic role in preventing the development of chronic hypoxia-induced PH, because of body weight loss and the subtle preventable effects of vascular changes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20606328     DOI: 10.1253/circj.cj-10-0097

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  6 in total

1.  Sarpogrelate hydrochloride, a serotonin 5HT2A receptor antagonist, ameliorates the development of chronic hypoxic pulmonary hypertension in rats.

Authors:  Erquan Zhang; Junko Maruyama; Ayumu Yokochi; Yoshihide Mitani; Hirofumi Sawada; Masakatsu Nishikawa; Ning Ma; Kazuo Maruyama
Journal:  J Anesth       Date:  2015-05-01       Impact factor: 2.078

2.  A wrinkle in time: circadian biology in pulmonary vascular health and disease.

Authors:  Andrew J Bryant; Elnaz Ebrahimi; Amy Nguyen; Christopher A Wolff; Michelle L Gumz; Andrew C Liu; Karyn A Esser
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2021-12-01       Impact factor: 5.464

3.  Effect of thrombomodulin on the development of monocrotaline-induced pulmonary hypertension.

Authors:  Yasuharu Yamada; Junko Maruyama; Erquan Zhang; Amphone Okada; Ayumu Yokochi; Hirofumi Sawada; Yoshihide Mitani; Tatsuya Hayashi; Koji Suzuki; Kazuo Maruyama
Journal:  J Anesth       Date:  2013-07-02       Impact factor: 2.078

4.  Lung damage created by high tidal volume ventilation in rats with monocrotaline-induced pulmonary hypertension.

Authors:  Masako Kawai; Erquan Zhang; Jane Chanda Kabwe; Amphone Okada; Junko Maruyama; Hirofumi Sawada; Kazuo Maruyama
Journal:  BMC Pulm Med       Date:  2022-03-05       Impact factor: 3.317

5.  Serine carboxypeptidase SCPEP1 and Cathepsin A play complementary roles in regulation of vasoconstriction via inactivation of endothelin-1.

Authors:  Xuefang Pan; Lubov Grigoryeva; Volkan Seyrantepe; Junzheng Peng; Katrin Kollmann; Johanne Tremblay; Julie L Lavoie; Aleksander Hinek; Torben Lübke; Alexey V Pshezhetsky
Journal:  PLoS Genet       Date:  2014-02-27       Impact factor: 5.917

Review 6.  Myeloid-Derived Suppressor Cells and Pulmonary Hypertension.

Authors:  Andrew J Bryant; Borna Mehrad; Todd M Brusko; James D West; Lyle L Moldawer
Journal:  Int J Mol Sci       Date:  2018-08-03       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.